Medical disclaimer: This page provides educational information about GLP-1 medications for people already working with a doctor. Nothing here constitutes medical advice, recommends specific medications, or replaces the guidance of a qualified UAE healthcare provider. GLP-1 medications are prescription medicines. Dosing, prescribing, suitability, side effects, and monitoring are medical decisions — coordinate everything with your doctor.
How both drugs work: the shared mechanism
Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) are both injectable medications that produce weight loss through overlapping but distinct mechanisms:
Semaglutide is a GLP-1 receptor agonist — it mimics the glucagon-like peptide-1 hormone that is naturally released after eating. GLP-1 receptors in the brain suppress appetite and in the gut slow gastric emptying (food moves through the stomach more slowly, extending fullness). The practical effect is a significant, sustained reduction in calorie intake.
Tirzepatide activates two receptors — GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) — which is why it is called a “dual agonist.” GIP receptor activation is thought to contribute additional weight-loss and metabolic effects beyond GLP-1 alone. This dual mechanism is generally considered the reason for tirzepatide’s greater average efficacy in trials.
Both medications produce weight loss by enforcing a calorie deficit through appetite suppression — not by directly burning fat or blocking absorption. The result is physiologically similar to a very significant dietary restriction, which is why the same muscle-preservation risks apply to both.
The weight-loss data: what the trials show
The most useful comparison comes from a meta-analysis published in PMC12151102 that analysed head-to-head trial data comparing tirzepatide and semaglutide:
| Medication | Average % bodyweight lost | Notes |
|---|---|---|
| Tirzepatide (Mounjaro) | ~20.2% | At the highest studied dose; SURMOUNT trials |
| Semaglutide (Ozempic/Wegovy) | ~13.7% | At the highest studied dose; STEP trials |
These figures are averages. Individual responses vary substantially — some people lose considerably more, some less, and some people stop responding to a medication after a period of use. Real-world results outside of trial conditions also tend to differ from trial averages.
What the data does not tell you:
- Which medication will work better for your specific physiology
- What dose will be appropriate for you
- Whether you are a suitable candidate for either medication
- How to manage the side-effect profile
These are all medical assessments — not questions a fitness coach should answer.
What both drugs have in common: the muscle-loss risk
Regardless of which medication is prescribed, both create the same core problem from a body-composition standpoint:
Without resistance training and adequate protein, 25–40% of the weight lost on GLP-1 medications can come from lean muscle mass rather than fat tissue. This is documented across clinical reviews for both semaglutide and tirzepatide.
The mechanism: the enforced calorie deficit from appetite suppression does not distinguish between fat and muscle as energy sources. In the absence of a resistance-training stimulus (which signals the body to preserve muscle) and adequate protein (which provides the substrate for muscle maintenance), the body mobilises muscle as fuel alongside fat.
The muscle-preservation protocol is identical regardless of which GLP-1 you are on:
- Protein at 1.6–2.0 g/kg of bodyweight per day — the primary muscle-sparing variable; per ISSN (PMC5477153)
- Resistance training 2–3 times per week — the biological signal that tells the body muscle is needed and should be retained
- Weekly weight-loss rate below ~1% of bodyweight — faster losses consistently show higher lean-mass loss; raise this with your doctor if your scale is dropping more than 1% weekly
This is PTD’s lane: protecting and building muscle while your doctor manages the medication. The two roles are entirely complementary — they cover different aspects of the same goal.
Coaching support alongside GLP-1 medication
No coaching role involves prescribing, recommending, or advising on medication — that is your doctor’s domain.
For clients using GLP-1 medications, PTD’s at-home training and nutrition coaching can support muscle preservation alongside your doctor’s care. The focus is on ensuring that the weight lost during GLP-1 therapy is fat, not muscle — and on building the muscle and metabolic foundation that makes weight maintenance more achievable when the medication eventually stops.
This kind of coaching support typically includes:
- Lean-mass tracking (e.g., STYKU 3D scanning) at regular check-ins — so lean-mass loss is detected promptly if it occurs
- Progressive resistance programming structured around your injection timing and energy patterns
- Protein targets and practical halal meal guidance for Dubai to hit 1.6–2.0 g/kg when appetite is suppressed
- Off-ramp planning — building the muscle and habits during the medication phase so your body is better positioned to maintain results after stopping
For the complete muscle-preservation and off-ramp protocol, see the GLP-1 insights guide. To establish your lean-mass baseline before or during medication, talk to a coach.
Medical disclaimer: The information on this page is educational and is not a substitute for medical advice from a qualified healthcare provider. GLP-1 medications (tirzepatide/Mounjaro, semaglutide/Ozempic, Wegovy) are prescription medicines. Dosing, safety, suitability, and medical management must be handled by a licensed UAE physician. PTD Fitness provides exercise and nutrition coaching as a complement to — not a replacement for — medical supervision. Always coordinate with your doctor.
Individual results vary.
